Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02

Richard K Valicenti, Michelle DeSilvio, Gerald E. Hanks, Arthur Porter, Harmar Brereton, Seth A. Rosenthal, William U. Shipley, Howard M. Sandler

Research output: Contribution to journalArticle

40 Scopus citations

Fingerprint Dive into the research topics of 'Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02'. Together they form a unique fingerprint.

Medicine & Life Sciences

Physics & Astronomy